Literature DB >> 5472209

Studies on the receptors involved in the action of the various agents in the phenylbenzoquinone analgesic assay in mice.

S E Smits, A E Takemori.   

Abstract

1. Tolerance to the activity of several narcotic analgesics (morphine, levorphanol, and methadone) and several narcotic-antagonist analgesics (pentazocine, cyclazocine, and nalorphine) was studied in the mouse phenylbenzoquinone stretching test. Virtually complete tolerance was induced by chronic treatment with each of the narcotic agents, while no apparent tolerance was induced by the narcotic antagonists.2. In morphine-tolerant mice there was a high degree of cross-tolerance to the effects of not only the other narcotic drugs but also to those of the narcotic antagonists, acetylsalicylic acid, and physostigmine.3. The effects of morphine and pentazocine were antagonized by naloxone but not by atropine, while the effects of physostigmine were antagonized by atropine but not by naloxone. Neither atropine nor naloxone antagonized the effect of acetylsalicylic acid.4. The results of the tolerance study suggest that there is a fundamental difference in the consequences of receptor interaction for the narcotic and the narcotic-antagonist analgesics. Morphine-tolerant mice exhibit cross-tolerance non-specifically. The selectivity of naloxone and atropine differentiates the narcotic and narcotic-analgesics from the other two agents used in this analgesic test.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5472209      PMCID: PMC1702619          DOI: 10.1111/j.1476-5381.1970.tb10371.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Antagonism of the frequency of phenylquinone-induced writhing in the mouse by weak analgesics and nonanalgesics.

Authors:  L C HENDERSHOT; J FORSAITH
Journal:  J Pharmacol Exp Ther       Date:  1959-03       Impact factor: 4.030

2.  A method for evaluating both non-narcotic and narcotic analgesics.

Authors:  E SIEGMUND; R CADMUS; G LU
Journal:  Proc Soc Exp Biol Med       Date:  1957 Aug-Sep

3.  Blockade of bradykinin-induced nociception in the rat as a test for analgesic drugs with particular reference to morphine antagonists.

Authors:  G F Blane
Journal:  J Pharm Pharmacol       Date:  1967-06       Impact factor: 3.765

4.  Inhibition of writhing by narcotic antagonists.

Authors:  J Pearl; L S Harris
Journal:  J Pharmacol Exp Ther       Date:  1966-11       Impact factor: 4.030

5.  Opioid and muscarinic anti-nociception.

Authors:  J D Ireson
Journal:  Br J Pharmacol       Date:  1969-10       Impact factor: 8.739

6.  Quantitative studies of the antagonism of morphine by nalorphine and naloxone.

Authors:  A E Takemori; H J Kupferberg; J W Miller
Journal:  J Pharmacol Exp Ther       Date:  1969-09       Impact factor: 4.030

7.  Agonist and antagonist interactions of opioids on acetic acid-induced abdominal stretching in mice.

Authors:  R I Taber; D D Greenhouse; J K Rendell; S Irwin
Journal:  J Pharmacol Exp Ther       Date:  1969-09       Impact factor: 4.030

8.  Agonist and antagonist actions of morphine-like drugs on the guinea-pig isolated ileum.

Authors:  E A Gyand; H W Kosterlitz
Journal:  Br J Pharmacol Chemother       Date:  1966-09

9.  Non-specificity of the mouse writhing test.

Authors:  H I Chernov; D E Wilson; W F Fowler; A J Plummer
Journal:  Arch Int Pharmacodyn Ther       Date:  1967-05

10.  Quantitative studies on the antagonism by naloxone of some narcotic and narcotic-antagonist analgesics.

Authors:  S E Smits; A E Takemori
Journal:  Br J Pharmacol       Date:  1970-07       Impact factor: 8.739

View more
  2 in total

1.  Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.

Authors:  A Cowan; J W Lewis; I R Macfarlane
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

Review 2.  Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.

Authors:  Jie Jiang; John Ravits
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.